Day: March 25, 2021

BILLERICA, Mass., March 25, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) hat heute bekanntgegeben, dass eine unabhängige, retrospektive Analyse von Krankenhausdaten zu dem Ergebnis gekommen ist, dass das Conformis iTotal®-Kniegelenkimplantat kostengünstiger ist als führende herkömmliche gebrauchsfertige Implantate. Wichtig anzumerken ist, dass diese Studie unabhängig durchgeführt wurde, d. h. ohne Sponsoring oder Finanzierung durch Conformis. Der neue Abstract wurde von den Autoren auf der Jahresversammlung der Orthopaedic Research Society 2021 (ORS 2021 Annual Meeting) vorgestellt, die im Februar 2021 stattfand: Custom-designed total knee arthroplasty is cost-effective in comparison to a standard implant (Maßgeschneiderte Knietotalendoprothese ist im Vergleich zu einem Standardimplantat kostengünstiger), Navin Fernando...

BILLERICA, Mass., March 25, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) ha anunciado hoy que un análisis retrospectivo e independiente de datos hospitalarios ha concluido que la tecnología de artroplastia de rodilla Conformis iTotal® es más rentable que los principales implantes tradicionales estandarizados. Es importante destacar que este estudio se realizó de forma independiente sin patrocinio ni financiación por parte de Conformis. Los autores presentaron el nuevo resumen en la reunión anual de la Sociedad de Investigación Ortopédica de 2021 (ORS 2021 Annual Meeting), celebrada en febrero de 2021: «Custom-designed total knee arthroplasty is cost-effective in comparison to a standard implant» (La artroplastia total de rodilla a medida es más rentable en comparación con un implante estándar), Dr. Navin Fernando, Ann Chancellor...

BILLERICA, Mass., March 25, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) kondigde vandaag aan dat een onafhankelijke, retrospectieve beoordeling van ziekenhuisgegevens heeft aangetoond dat Conformis iTotal® knievervangingstechnologie kostenefficiënter is dan conventionele gebruikelijke standaardimplantaten. Belangrijk is dat dit onderzoek onafhankelijk is uitgevoerd, zonder sponsoring of financiering door Conformis. Het nieuwe abstract werd gepresenteerd door auteurs tijdens de jaarlijkse bijeenkomst van de Orthopedic Research Society 2021 (ORS 2021 Annual Meeting), in februari 2021: Op maat ontworpen totale knie-artroplastiek is kostenefficiënt in vergelijking met een standaardimplantaat, Navin Fernando MD, Ann Chancellor CCRC, Paul Manner MD, University of Washington, Seattle, WA, 2021 Proceedings of Orthopedic Research...

Midland, TX, March 25, 2021 (GLOBE NEWSWIRE) — Natural Gas Services Group, Inc. (NYSE:NGS), a leading provider of gas compression equipment and services to the natural gas industry, announces  the following conference call information for their fourth quarter and full year 2020 earnings release: Earnings Release: Tuesday, March 30, 2021 before market opens Public distribution will be through Nasdaq OMX and the Natural Gas Services Group, Inc. website at www.ngsgi.com. Conference Call: Tuesday, March 30, 2021 at 10:00 a.m. Central, 11:00 a.m. Eastern  Live via phone by dialing 877-358-7306, pass code “Natural Gas Services”. All attendees and participants to the conference call should arrange to call in at least 5 minutes prior to the start time. Conference Call Replay For those unable to attend the live teleconference,...

Samningur um viðskiptavakt á eftirmarkaði með skuldabréf Reykjavíkurborgar, RVK 53 1, RVK 32 1, RVKN35 1 og RVKG 48 1 Þann 25. mars 2021 samþykkti borgarráð að endurnýja samninga við Arion banka hf., Íslandsbanka hf., Kviku banka hf. og Landsbankann hf. um viðskiptavakt með skuldabréfaflokkana RVK 53 1, RVK 32 1, RVKN 35 1. Einnig er samið um viðskiptavakt um skuldabréfaflokkinn RVKG 48 1, sem hefst eftir fyrsta útboð í flokkinum á samningstímanum. Tilgangur samningsins er að efla viðskipti með þau skuldabréf sem samningurinn tekur til, auka seljanleika þeirra á eftirmarkaði og stuðla að eðlilegri verðmyndun.Viðskiptavakt Arion banka hf., Íslandsbanka hf., Kviku banka hf., Landsbankans hf., gildir frá og með 1. apríl 2021 til 31. mars 2022. Helstu atriði samningsins eru: Viðskiptavakar skuldbinda sig til að setja fram dagleg kaup- og...

TEMPE, Ariz., March 25, 2021 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (the “Company” or “WRAP”) (Nasdaq: WRAP), a global leader in innovative public safety technologies and services, released new bodycam footage of a successful BolaWrap deployment restraining a non-compliant subject. On Wednesday, March 17, 2021, Glenwood Springs Police Department in Colorado responded to a male subject in crisis, running in traffic and endangering himself and other motorists. Bodycam footage of the incident can be viewed on the Company’s YouTube channel here. “This incident is an excellent example of the importance of providing officers with the best tools and best training to deal with the challenges they face each day involving people in crisis,” said Mike Rothans, Chief Strategy Officer at Wrap and...

NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) — Better Choice Company (OTCQX: BTTR) (“Better Choice”), an animal health and wellness company, today announced its plans to enter the freeze-dried market for dog and cat food internationally, adding to its strong lineup of products already sold to Asian consumers under the Halo brand. This expansion opportunity represents an additional growth opportunity to the previously announced minimum purchases with the Company’s Asian distribution partners, totaling $25.6 million in aggregate sales over the next two years. Better Choice anticipates that these products will be sold under the popular Halo brand through its existing distribution partner network in Asia, with a particular focus on China, Korea and Japan. Halo’s commitment to product quality has resonated strongly with Asian pet parents...

Boliga Gruppen A/SCVR.nr. 25078780 (“Selskabet”)Fondsbørsmeddelelse nr. 1/2021 Den samlede omsætning i koncernen blev 56 mDKK i 2020 mod 49 mDKK i 2019. Omsætningen ligger på de senest udmeldte forventninger om en omsætning i 2020 på ca. 54-57 mDKK. Egenbeholdningen af pantebreve andrager pr. 31.12.2020 33,5 mDKK. Resultat af primært driftKoncernens samlede resultat af primær drift blev 15,8 mDKK i 2020 mod 7,1 mDKK i 2019. Resultat før skatResultatet før skat for koncernen blev 13,3 mDKK i 2020 mod 7,8 mDKK i 2019. Resultatet ligger på niveau med de senest udmeldte forventninger om et resultat på 12-14 mDKK. Årets resultatSom følge af ovenstående blev årets resultat efter skat 9,7 mDKK i 2020 mod 7,1 mDKK i 2019. Forventninger til 2021 for koncernenI 2021 forventer ledelsen en omsætning på mDKK 57-59 samt et resultat før skat på mDKK...

TORONTO, March 25, 2021 (GLOBE NEWSWIRE) — Labrador Gold Corp. (TSX.V:LAB | OTCQX:NKOSF | FNR: 2N6) (“LabGold” or the “Company”) is pleased to announce the mobilization of drill and field crew to its 100% controlled Kingsway Gold Project near Gander, Newfoundland. The Kingsway project is located within the highly prospective Gander Gold District and along strike from New Found Gold’s high-grade Queensway Project. Since Labgold is already well advanced in its preparations for the drilling program it is expected that drilling will begin in the next few days. The 10,000 metre drill program, anticipated to consist of 43 holes, is designed to test a 350-metre strike length of Big Vein. Initial drilling is designed to test shallow mineralization below the original visible gold showing, a grab sample from which assayed 1,065 g/t gold (see...

Validive®Phase 2b/3 VOICE Clinical Trial CommencedCamsirubicin Phase 2 Clinical Trial Anticipated to Start in Q2 2021MNPR-101-Conjugate Data Published in European Journal of Cancer WILMETTE, Ill., March 25, 2021 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced fourth quarter and full-year 2020 financial results and recent business updates. Recent Business Updates Lead Product Candidate ValidiveMonopar’s Phase 2b/3 VOICE clinical trial of Validive (clonidine HCl mucobuccal tablet) for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) for oropharyngeal cancer (OPC)...